Tolerability of 5 mg Solifenacin Once Daily Versus 5 mg Oxybutynin Immediate Release 3 Times Daily: Results of the VECTOR Trial-Reference-Cited by-同舟云学术

Tolerability of 5 mg Solifenacin Once Daily Versus 5 mg Oxybutynin Immediate Release 3 Times Daily: Results of the VECTOR Trial

Published:2010-05 Issue:5 Volume:183 Page:1892-1898
ISSN:0022-5347
Container-title:Journal of Urology
language:en
Short-container-title:Journal of Urology

Author:

Herschorn Sender¹,Stothers Lynn²,Carlson Kevin³,Egerdie Blair⁴,Gajewski Jerzy B.⁵,Pommerville Peter⁶,Schulz Jane⁷,Radomski Sidney¹,Drutz Harold⁸,Barkin Jack⁹,Paradiso-Hardy Fran¹⁰

Affiliation:

1. Department of Surgery/Urology, University of Toronto, Toronto, Ontario, Canada

2. University of British Columbia, Bladder Care Centre, Victoria, British Columbia, Canada

3. Division of Urology, University of Calgary, Calgary, Alberta, Canada

4. Urology Associates/Urologic Medical Research, Markham, Ontario, Canada

5. Department of Urology, Dalhousie University, Halifax, Nova Scotia, Canada

6. Can-Med Clinical Research, Inc., Victoria, British Columbia, Canada

7. Department of Obstetrics and Gynecology, Royal Alexandra Hospital, University of Alberta, Edmonton, Alberta, Canada

8. Department of Obstetrics and Gynecology, University of Toronto, Toronto, Ontario, Canada

9. Department of Surgery, University of Toronto, Toronto, Ontario, Canada

10. Kitchener and Astellas Pharma Canada, Markham, Ontario, Canada

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Urology

Reference25 articles.

1. A population-based study of urinary symptoms and incontinence: the Canadian Urinary Bladder Survey;Herschorn;BJU Int,2008

2. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study;Irwin;Eur Urol,2006

3. Comorbidities associated with overactive bladder;Brown;Am J Manag Care,2000

4. New frontiers in the treatment of overactive bladder and incontinence;Chancellor;Rev Urol,2002

5. The implications of poor medication persistence with treatment for overactive bladder;Noe;Manag Care Interface,2004

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Retrospective Database Analysis to Investigate Treatment Patterns and Health Care Resource Utilisation in Patients who CYCLe AntiMuscarinics in ENgland (CYCLAMEN);European Urology Focus;2023-10

2. Mirabegron and Anticholinergics in the Treatment of Overactive Bladder Syndrome: A Meta-analysis;Revista Brasileira de Ginecologia e Obstetrícia / RBGO Gynecology and Obstetrics;2023-06

3. Diagnosis and management of overactive bladder: A review;Journal of Obstetrics and Gynaecology Research;2021-02-16

4. THE PHARMACOTHERAPY TIME-TO-EFFECT OF OVERACTIVE BLADDER MEDICATIONS AND TREATMENT DURATION;Acta Poloniae Pharmaceutica - Drug Research;2020-06-29

5. Percutaneous tibial nerve stimulation associated with occipital headaches: a review of the adverse effects of percutaneous tibial nerve stimulation;Obstetrics & Gynecology International Journal;2018-10-08